specialists in coagulation testing









Glaxosmithkline names Machaon a reference site for ARIXTRA.
GLAXOSMITHKLINE NAMES MACHAON DIAGNOSTICS A REFERENCE SITE FOR THE CLINICAL TESTING OF ARIXTRA.
1/7/2008 San Francisco, CA – GlaxoSmithKline names Machaon Diagnostics a reference site for the clinical testing of fondaparinux sodium (Arixtra). GlaxoSmithKline PLC, the world’s third largest pharmaceutical manufacturing company, is committed to discovering new ways to treat disease, making sure patients get their medicines, and making a difference in the community.

ARIXTRA (fondaparinux sodium) is a synthetic factor Xa antagonist used in the treatment of deep venous thrombosis (DVT), pulmonary embolism (PE) and other thrombotic complications (1, 3). The prothrombin time (PT) and activated partial thromboplastin time (aPTT) are insensitive to fondaparinux and unsuitable for monitoring (1, 2). ARIXTRA level monitoring has been recommended in special populations such as renal impairment, hepatic impairment, elderly patients and patients weighing less than 50kg (1).

References:
1. Prescribing Information. ARIXTRA.
2. Walenga JM et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs. 2002 Mar;11(3):397-407.
3. Mehta SR et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol. 2007 Oct 30;50(18):1742-51. Epub 2007 Oct 15.
 
© 2014 Machaon Diagnostics, Inc.